X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through the agreement, Collegium will exclusively manufacture and supply Hikma with all authorized generic products for sale, including Nucynta-Generic (tapentadol HCl).
Lead Product(s): Tapentadol
Therapeutic Area: Neurology Product Name: Nucynta-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 29, 2024
Details:
Assertio Therapeutics has entered into a definitive agreement with Collegium Pharmaceutical, Inc. under which Collegium will acquire the NUCYNTA® franchise of products from the Company.
Lead Product(s): Tapentadol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Collegium Pharmaceutical
Deal Size: $375.0 million Upfront Cash: $375.0 million
Deal Type: Agreement February 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
